Edward Breitschwerdt, DVM
Chief Scientific Officer
Dr. Breitschwerdt is an internist and professor of medicine and infectious diseases at North Carolina State University’s College of Veterinary Medicine. He is a co-director of the Vector Borne Disease Diagnostic Laboratory which has been testing animals for vector borne infections, including Bartonella since 1984. With over 200 peer-reviewed publications, Dr. Breitschwerdt is a internationally recognized leader in the area of Bartonella research, diagnosis, and treatment. As a consequence, he has been consulted widely upon an array of infectious diseases for many leading companies in the veterinary diagnostics, therapeutic, and vaccine industries. Dr. Breitschwerdt’s research at the NCSU Intracellular Pathogens Research Laboratory has produced significant research findings concerning the medical importance of Bartonella and other emerging infectious disease pathogens.
Amanda B. Elam, PhD
Dr. Elam holds a doctorate in Sociology from the University of North Carolina at Chapel Hill and has published extensively on the topic of business start-up. Her doctoral research on entrepreneurship has been recognized by the Academy of Management for innovative thought leadership. Prior to joining the Galaxy team, Dr. Elam recently completed two years of Postdoctoral Research at top-ranked schools of management and entrepreneurship, including the Queensland University of Technology in Brisbane, Australia and Babson College in Wellesley, Massachusetts. Dr. Elam is a Lecturer in the department of Management, Innovation, and Entrepreneurship at NC State University. Dr. Elam is responsible for all day-to-day operations and business development activities at Galaxy.
Ricardo Maggi, PhD
Chief Technical Officer
Dr. Maggi holds a doctorate in molecular biology and is an Assistant Professor of Medical Microbiology at the College of Veterinary Medicine at North Carolina State University. Dr. Maggi brings an exceptional and diverse background in molecular biology to Galaxy. He played an integral role in the development of our proprietary diagnostic technology and directs all assay development and quality control activities for both Animal and Human Health services.
B. Robert Mozayeni, MD
Chief Medical Officer
Dr. Mozayeni is a Rheumatologist with graduate and post-graduate physician-scientist training from Albany Medical College, Yale University, Howard Hughes Medical Institute, and the National Institutes of Health (NCI, NHLBI, and NIAMS). He is presently in private practice in Bethesda, MD where he specializes in chronic inflammatory diseases having rheumatic and neurovascular manifestations. Dr. Mozayeni is the founder and Executive Director of the Translational Medicine Group where he has developed and commercialized software that supports data-driven methods to accelerate the evaluation and improvement of patient-centered care pathways. Under an ongoing research collaboration with Dr. Breitschwerdt, Dr. Mozayeni maintains an observational clinical evaluation of the significance of Bartonella infection in a cohort of several hundred human patients with otherwise unexplained chronic conditions. Clinical correlations between Bartonella species and various conditions are being determined as part of ongoing research which continues to redefine diagnostic and therapeutic options as dictated by clinical experience.